Journal article
Radionuklidbehandling af neuroendokrine tumorer
Copenhagen University Hospital Herlev and Gentofte1
Management, Risø National Laboratory for Sustainable Energy, Technical University of Denmark2
Risø National Laboratory for Sustainable Energy, Technical University of Denmark3
Biomedical Tracers, Radiation Research Division, Risø National Laboratory for Sustainable Energy, Technical University of Denmark4
Radiation Research Division, Risø National Laboratory for Sustainable Energy, Technical University of Denmark5
Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with 177 Lu-DOTATATE treatment used at Rigshospitalet.
Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
Language: | Danish |
---|---|
Year: | 2010 |
Pages: | 2950-2953 |
ISSN: | 16036824 , 13994174 and 00415782 |
Types: | Journal article |
ORCIDs: | 0000-0002-2706-5547 |